P Rubinstein

6.9k total citations · 1 hit paper
139 papers, 4.7k citations indexed

About

P Rubinstein is a scholar working on Immunology, Hematology and Oncology. According to data from OpenAlex, P Rubinstein has authored 139 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Immunology, 37 papers in Hematology and 31 papers in Oncology. Recurrent topics in P Rubinstein's work include Viral-associated cancers and disorders (25 papers), Blood groups and transfusion (19 papers) and Diabetes and associated disorders (18 papers). P Rubinstein is often cited by papers focused on Viral-associated cancers and disorders (25 papers), Blood groups and transfusion (19 papers) and Diabetes and associated disorders (18 papers). P Rubinstein collaborates with scholars based in United States, France and Spain. P Rubinstein's co-authors include C.T. Falk, Santiago Rodrı́guez de Córdoba, Cladd E. Stevens, J W Adamson, P. E. Taylor, Giovanni Migliaccio, Ludy Dobrila, Anna Ritá Migliaccio, R. E. Rosenfield and Margaret E. Nichols and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

P Rubinstein

130 papers receiving 4.5k citations

Hit Papers

Processing and cryopreservation of placental/umbilical co... 1995 2026 2005 2015 1995 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P Rubinstein United States 33 1.5k 1.4k 1.1k 934 805 139 4.7k
Cristina Navarrete United Kingdom 36 1.4k 0.9× 1.3k 1.0× 384 0.3× 999 1.1× 877 1.1× 120 4.4k
Mario Abinun United Kingdom 34 1.1k 0.7× 1.9k 1.4× 831 0.7× 563 0.6× 1.2k 1.5× 107 4.3k
Élie Haddad Canada 46 1.9k 1.2× 3.2k 2.4× 1.0k 0.9× 615 0.7× 1.4k 1.7× 179 6.9k
Wilma Β. Bias United States 47 1.1k 0.7× 2.7k 2.0× 1.1k 1.0× 326 0.3× 882 1.1× 160 7.3k
Jon J. van Rood Netherlands 42 2.5k 1.6× 3.5k 2.6× 618 0.5× 574 0.6× 626 0.8× 114 6.5k
Shunichi Kato Japan 43 3.0k 1.9× 2.2k 1.6× 386 0.3× 1.1k 1.2× 1.4k 1.8× 171 6.2k
Paul Szabolcs United States 29 1.7k 1.1× 2.5k 1.9× 486 0.4× 648 0.7× 577 0.7× 111 4.8k
W Wiktor-Jędrzejczak Poland 30 1.8k 1.2× 1.9k 1.4× 409 0.4× 871 0.9× 2.0k 2.5× 222 5.5k
Juan J. Yunis United States 38 868 0.6× 1.3k 0.9× 1.3k 1.2× 483 0.5× 1.5k 1.9× 173 4.8k
H. Grosse‐Wilde Germany 32 851 0.6× 2.0k 1.5× 390 0.3× 401 0.4× 425 0.5× 168 3.6k

Countries citing papers authored by P Rubinstein

Since Specialization
Citations

This map shows the geographic impact of P Rubinstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Rubinstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Rubinstein more than expected).

Fields of papers citing papers by P Rubinstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P Rubinstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Rubinstein. The network helps show where P Rubinstein may publish in the future.

Co-authorship network of co-authors of P Rubinstein

This figure shows the co-authorship network connecting the top 25 collaborators of P Rubinstein. A scholar is included among the top collaborators of P Rubinstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P Rubinstein. P Rubinstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Noy, Ariela, Stefan K. Barta, Deukwoo Kwon, et al.. (2024). Daratumumab with Dose-Adjusted EPOCH Is Feasible in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105. Blood. 144(Supplement 1). 870–870.
2.
Rajdev, Lakshmi, Himanshu Joshi, Shelly Lensing, et al.. (2023). Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study. Cancer. 130(6). 985–994. 6 indexed citations
3.
Rubinstein, P, et al.. (2022). CD30 + Primary intestinal T-cell lymphoma (unclassified) masquerading as chronic inflammation: a case report. Diagnostic Pathology. 17(1). 53–53. 3 indexed citations
4.
Cesarman, Ethel, Amy Chadburn, & P Rubinstein. (2021). KSHV/HHV8-mediated hematologic diseases. Blood. 139(7). 1013–1025. 75 indexed citations
5.
Mahale, Parag, Jason Nomburg, Joo Y. Song, et al.. (2021). Metagenomic analysis to identify novel infectious agents in systemic anaplastic large cell lymphoma. Infectious Agents and Cancer. 16(1). 65–65. 1 indexed citations
6.
Ramos, Juan Carlos, Joseph A. Sparano, Amy Chadburn, et al.. (2020). Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). Blood. 136(11). 1284–1297. 36 indexed citations
7.
Rajdev, Lakshmi, Shelly Lensing, Juan Carlos Ramos, et al.. (2020). 1023MO AMC 095: A report of nivolumab (nivo) in advanced HIV associated solid tumours (ST). Annals of Oncology. 31. S706–S706. 5 indexed citations
8.
Qian, Edward, et al.. (2019). Pernicious Anemia Presenting With Pseudo Thrombotic Microangiopathy and Falsely Elevated B 12 Levels. Journal of Hematology. 8(3). 129–131. 5 indexed citations
9.
Ramos, Juan Carlos, Joseph A. Sparano, Page C. Moore, et al.. (2018). AMC075: A randomized phase II trial of vorinostat with R-EPOCH in aggressive HIV-related NHL.. Journal of Clinical Oncology. 36(15_suppl). 7573–7573. 2 indexed citations
10.
Haigentz, Missak, Page C. Moore, Lee Ratner, et al.. (2017). Tolerability of paclitaxel/carboplatin (PCb) in solid tumor patients (pts) infected with HIV.. Journal of Clinical Oncology. 35(15_suppl). e14077–e14077. 1 indexed citations
11.
Gluckman, Éliane, et al.. (2000). Cord Blood Characteristics: Role in Stem Cell Transplantation. UCL Discovery (University College London). 17 indexed citations
12.
McEvoy, Robert C., et al.. (1996). Anti-islet autoantibodies detected by monoclonal antibody 1A2: further studies suggesting a role in the pathogenesis of IDDM. Diabetologia. 39(11). 1365–1371. 3 indexed citations
13.
Khanna, Ashwani, Daniel R. Buskirk, Ralph C. Williams, et al.. (1989). Presence of a non-HLA B cell antigen in rheumatic fever patients and their families as defined by a monoclonal antibody.. Journal of Clinical Investigation. 83(5). 1710–1716. 115 indexed citations
14.
Barnwell, John W., Margaret E. Nichols, & P Rubinstein. (1989). In vitro evaluation of the role of the Duffy blood group in erythrocyte invasion by Plasmodium vivax.. The Journal of Experimental Medicine. 169(5). 1795–1802. 170 indexed citations
16.
Walker, Mirjam, et al.. (1989). RFrAP: A computer program for analysis of complex HLA RFLPs. Human Immunology. 25(1). 13–26. 1 indexed citations
17.
Rubinstein, P, et al.. (1979). Glyoxalase 1: A Possible ‘Null’ Allele. Human Heredity. 29(4). 217–220. 7 indexed citations
18.
Suciu‐Foca, Nicole, et al.. (1977). A new technique for the preparation of B cells for typing.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 9(4). 1715–6. 2 indexed citations
19.
Suciu‐Foca, Nicole & P Rubinstein. (1977). Immunogenetics of the HLA system. Genetic fine structure of the HLA region.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 9(1). 385–91. 4 indexed citations
20.
Rubinstein, P, et al.. (1968). Experience of histoplasmosis in the Muñiz Hospital and the Mycology Centre.. 17(1). 50–55. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026